Influence of disease duration in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease duration on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…Opicapone odds ratio in relative OFF-time reduction: a post-hoc analysis from combined BIPARK-I and II data
Objective: To evaluate the opicapone (OPC) associated patient’s odds ratio (OR) in relative OFF-time reduction. Background: OPC, a once-daily COMT inhibitor, proved effective in the…Influence of disease severity in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of disease severity on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations. Background: OPC,…Addition of Opicapone to Safinamide in Parkinson’s Disease patients
Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…Opicapone as a levodopa sparing agent: pooled analysis of BIPARK-I and II double-blind trials
Objective: To evaluate, in levodopa-treated Parkinson’s Disease (PD) patients, the ability of opicapone (OPC) to act as levodopa-sparing agent. Background: OPC, a once-daily COMT inhibitor,…Influence of demographic characteristics in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of demographic characteristics in the efficacy response of levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: Opicapone (OPC), a…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline body mass index: post-hoc analysis from double-blind combined BIPARK-I and II data.
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Influence of motor fluctuations duration, levodopa dose and duration of use in efficacy responses of Parkinson’s disease patients: post-hoc analysis from combined BIPARK-I and II.
Objective: To evaluate the impact of motor fluctuations (MF) duration, levodopa dose and levodopa duration of use (LDU) in efficacy responses of levodopa-treated Parkinson’s Disease…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline dopamine agonist use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the impact of baseline OFF-time on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 11
- Next Page »